Bristol Myers Squibb’s Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with ...

The randomized, double-blind, placebo-controlled ODYSSEY-HCM trial included 580 adult patients with symptomatic nonobstructive HCM.

Bristol Myers Squibb announced that mavacamten did not achieve statistical significance in meeting the dual primary endpoints ...

Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether ...

Vascular & Thoracic Institute and Director of the HCM Center, Cleveland Clinic. “The findings of this trial help us understand that obstructive HCM and non-obstructive HCM are two unique diseases.

Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association (NYHA) ...